Tus-Pharmaceutical Group Dirección

Dirección controles de criterios 3/4

Actualmente no disponemos de información suficiente sobre el CEO.

Información clave

Xue Feng

Chief Executive Officer (CEO)

n/a

Compensación total

Porcentaje del salario del CEO	n/a
Permanencia del CEO	4.5yrs
Participación del CEO	n/a
Permanencia media de la dirección	4.5yrs
Promedio de permanencia en la Junta Directiva	3.9yrs

Actualizaciones recientes de la dirección

Recent updates

Tus-Pharmaceutical Group Co., Ltd.'s (SZSE:000590) 37% Price Boost Is Out Of Tune With Revenues

Nov 08

Tus-Pharmaceutical Group's (SZSE:000590) Solid Profits Have Weak Fundamentals

Apr 03

Revenues Not Telling The Story For Tus-Pharmaceutical Group Co., Ltd. (SZSE:000590) After Shares Rise 27%

Mar 08

CEO

Xue Feng (34 yo)

4.5yrs

Permanencia

CN¥420,000

Compensación

Mr. Xue Feng serves as the Non Independent Director of Tus-Pharmaceutical Group Co., Ltd. (formerly known as Tus-Guhan Group Corp.,Ltd.) since May 21, 2020 and serves as its President.

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Ting Tang	VP, CFO & Non Independent Director	7.9yrs	CN¥370.00k	sin datos
Dingxing Cao	VP & Board Secretary	no data	CN¥370.00k	sin datos
Jun Cai	Vice President	1.5yrs	CN¥345.00k	sin datos
Xue Feng	President & Non Independent Director	4.5yrs	CN¥420.00k	sin datos

4.5yrs

Permanencia media

44yo

Promedio de edad

Equipo directivo experimentado: El equipo directivo de 000590 se considera experimentado (4.5 años antigüedad media).

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Ting Tang	VP, CFO & Non Independent Director	7.9yrs	CN¥370.00k	sin datos
Xue Feng	President & Non Independent Director	4.5yrs	CN¥420.00k	sin datos
Kebiao Yan	Chairman of the Board of Supervisors	7.4yrs	sin datos	sin datos
Qisen Jiao	Chairman of the Board	4.1yrs	CN¥420.00k	sin datos
Zhengming Huang	Independent Director	3.9yrs	CN¥120.00k	sin datos
Jingwei Sun	Supervisor	3.9yrs	sin datos	sin datos
Xiaoqiao Ni	Vice Chairman	1.5yrs	sin datos	sin datos
Zhenhua Lei	Independent Director	1.5yrs	CN¥70.00k	sin datos
Wenbiao Huang	Independent Director	1.5yrs	sin datos	sin datos

3.9yrs

Permanencia media

50yo

Promedio de edad

Junta con experiencia: La junta directiva de 000590 se considera experimentada (3.9 años de antigüedad promedio).

Tus-Pharmaceutical Group Dirección

Dirección controles de criterios 3/4

Información clave

Actualizaciones recientes de la dirección

Tus-Pharmaceutical Group Co., Ltd., Annual General Meeting, Jun 28, 2024

High number of new and inexperienced directors

Tus-Pharmaceutical Group Co., Ltd. Approves Board Appointments

High number of new directors

Tus-Pharmaceutical Group Co., Ltd., Annual General Meeting, Jun 30, 2022

High number of new and inexperienced directors

Recent updates

Tus-Pharmaceutical Group Co., Ltd.'s (SZSE:000590) 37% Price Boost Is Out Of Tune With Revenues

Third quarter 2024 earnings released: CN¥0.021 loss per share (vs CN¥0 in 3Q 2023)

Tus-Pharmaceutical Group Co., Ltd. to Report Q3, 2024 Results on Oct 30, 2024

Second quarter 2024 earnings released: CN¥0.063 loss per share (vs CN¥0.001 loss in 2Q 2023)

Tus-Pharmaceutical Group Co., Ltd. to Report First Half, 2024 Results on Aug 29, 2024

Tus-Pharmaceutical Group Co., Ltd., Annual General Meeting, Jun 28, 2024

New minor risk - Share price stability

First quarter 2024 earnings released: CN¥0.035 loss per share (vs CN¥0.028 profit in 1Q 2023)

Investor sentiment deteriorates as stock falls 26%

Tus-Pharmaceutical Group's (SZSE:000590) Solid Profits Have Weak Fundamentals

Tus-Pharmaceutical Group Co., Ltd. to Report Q1, 2024 Results on Apr 26, 2024

Full year 2023 earnings released: EPS: CN¥0.10 (vs CN¥0.076 in FY 2022)

Revenues Not Telling The Story For Tus-Pharmaceutical Group Co., Ltd. (SZSE:000590) After Shares Rise 27%

New minor risk - Share price stability

Tus-Pharmaceutical Group Co., Ltd. to Report Fiscal Year 2023 Results on Mar 28, 2024

New minor risk - Earnings quality

Third quarter 2023 earnings released: EPS: CN¥0 (vs CN¥0.017 in 3Q 2022)

Tus-Pharmaceutical Group Co., Ltd. to Report Q3, 2023 Results on Oct 28, 2023

New minor risk - Earnings quality

Second quarter 2023 earnings released: CN¥0.001 loss per share (vs CN¥0.004 loss in 2Q 2022)

Tus-Pharmaceutical Group Co., Ltd. to Report First Half, 2023 Results on Aug 23, 2023

High number of new and inexperienced directors

Tus-Pharmaceutical Group Co., Ltd. Approves Board Appointments

Full year 2022 earnings released: EPS: CN¥0.076 (vs CN¥0.15 in FY 2021)

High number of new directors

Third quarter 2022 earnings released: EPS: CN¥0.017 (vs CN¥0.041 in 3Q 2021)

Second quarter 2022 earnings released: CN¥0.004 loss per share (vs CN¥0.036 profit in 2Q 2021)

Tus-Pharmaceutical Group Co., Ltd. (SZSE:000590) completed the acquisition of Guangdong Sinotau Pharmaceutical Co., Ltd. from Beijing Xiantongyuan Pharmaceutical Technology Co., Ltd. and Li Yinqiang.

Tus-Pharmaceutical Group Co., Ltd., Annual General Meeting, Jun 30, 2022

First quarter 2022 earnings released: EPS: CN¥0.052 (vs CN¥0.085 in 1Q 2021)

High number of new and inexperienced directors

Investor sentiment deteriorated over the past week

Full year 2021 earnings released: EPS: CN¥0.15 (vs CN¥0.095 in FY 2020)

Investor sentiment deteriorated over the past week

Third quarter 2021 earnings released: EPS CN¥0.041 (vs CN¥0.023 in 3Q 2020)

Second quarter 2021 earnings released: EPS CN¥0.036 (vs CN¥0.021 in 2Q 2020)

First quarter 2021 earnings released: EPS CN¥0.085 (vs CN¥0.037 in 1Q 2020)

Full year 2020 earnings released: EPS CN¥0.095 (vs CN¥0.18 in FY 2019)

Tus-Pharmaceutical Group Co., Ltd. to Report Fiscal Year 2020 Results on Mar 30, 2021

New 90-day low: CN¥7.77

New 90-day low: CN¥8.29

New 90-day low: CN¥9.42

Tus-Guhan Group Corp.,Ltd. Approves Board Elections

New 90-day low: CN¥9.45

Tus-Guhan Group Corp.,Ltd. Approves Election of Jiao Qisen as A Non-Independent Director

New 90-day low: CN¥9.55

New 90-day low: CN¥9.84

New 90-day high - CN¥12.57

Tus-Guhan Group Corp.,Ltd. to Report First Half, 2020 Results on Aug 28, 2020

CEO

Permanencia

Compensación

Equipo directivo

Permanencia media

Promedio de edad

Miembros de la Junta

Permanencia media

Promedio de edad